Business Context and Reporting Period
This Form 8-K filing by Dermata Therapeutics, Inc. (DRMA) is dated May 14, 2024. The report addresses the Company's status regarding Nasdaq listing compliance and updates risk factors related to potential delisting.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and listing status.
Material Changes and Listing Status
- Nasdaq Non-Compliance: The Company remains non-compliant with Nasdaq Listing Rule 5550(a)(2) due to a failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days.
- Compliance Extension: On May 14, 2024, Nasdaq granted the Company a 180-day extension to regain compliance, with a new deadline of November 11, 2024.
- Reverse Stock Split: To address the non-compliance, the Company filed a Certificate of Amendment to effect a one-for-fifteen (1:15) reverse stock split. This action is scheduled to take effect at 12:01 a.m. Eastern Time on May 16, 2024.
Outlook, Risks, and Management Commentary
Management acknowledges there is no assurance that the reverse stock split will result in compliance with the Minimum Bid Price Requirement or other Nasdaq listing rules within the extended period. If compliance is not achieved by November 11, 2024, the Company's Common Stock and Warrants (DRMAW) will be subject to delisting.
Material risks associated with potential delisting include:
- Substantial decrease in trading volume and market liquidity.
- Loss of market efficiencies and federal preemption of state securities laws.
- Adverse impact on the ability to obtain financing on acceptable terms.
- Potential loss of confidence among investors, suppliers, customers, and employees.
- Further decline in the market price of Common Stock and Warrants.
Investor Verification Checklist
- Verify the effective date and execution of the 1:15 reverse stock split on May 16, 2024.
- Monitor the post-split closing bid price to assess if it meets the $1.00 minimum requirement.
- Review the Company's capital position to determine if additional financing is needed to sustain operations.
- Check for any subsequent Nasdaq communications regarding the Company's compliance status before the November 11, 2024 deadline.